| Objective: Colorectal cancer is a common tumor of the digestive system.The treatment plan is mainly surgery,supplemented by radiotherapy,chemotherapy and other treatment methods.In recent years,the treatment of colorectal cancer with hyperthermic intraperitoneal chemotherapy has attracted more and more attention.This study intends to explore Patients with stage T3 and T4 colorectal cancer undergoing early hyperthermic intraperitoneal chemotherapy with lobaplatin combined with intravenous chemotherapy after radical resection of colorectal cancer have effects on blood cells,liver and kidney function,postoperative complications or adverse reactions,tumor markers,recurrence and metastasis rate and the impact of survival rate.Methods: A retrospective analysis of the clinical data of 92 patients with T3 and T4 colorectal cancer in the Second Ward of General Surgery of the First Hospital of Qinhuangdao City from February 2018 to February 2019.According to whether or not they received Hyperthermic Intraperitoneal Chemotherapy(HIPEC)were divided into 48 cases in HIPEC group and 44 cases in control group.Patients in HIPEC group received intraperitoneal hyperthermic perfusion of lobaplatin combined with XELOX intravenous chemotherapy after radical resection of colorectal cancer.Patients in control group received only XELOX intravenous chemotherapy after radical resection of colorectal cancer.The independent sample t-test and chi-square test were used to compare the differences in white blood cells,hemoglobin,platelets,liver and kidney functions and postoperative adverse reactions or complications between the two groups on the 4th and 7th days after surgery.Meanwhile,the differences in tumor markers,recurrence and metastasis rates and survival rates between the two groups at 6 months,1 year and 2 years after surgery were analyzed.Results:1.Safety of HIPEC in patients with colorectal cancerOn the 4th and 7th day after the operation,the urea value of HIPEC group was lower than that of the control group(6.01±1.74 vs.5.25±1.39,6.45±2.27 vs.5.55±1.29,all P<0.05).There were no significant differences in white blood cells,hemoglobin,platelet,alanine transaminase,total bilirubin,albumin and creatinine between the HIPEC group and the control group on the4 th and 7th day after surgery(P > 0.05).There was no significant difference in postoperative recovery and complication rate between the two groups(P >0.05).2.The influence of HIPEC on colorectal cancer related tumor markersThe positive rate of CEA in the HIPEC group was lower than that in the control group(14.58% vs.34.09% P<0.05)after 2 years.There was no significant difference between the HIPEC group and the control group in the AFP and CA19-9 at 6 months,1 year,and 2 years after the operation,and the CEA between the two groups at 6 months and 1 year after the operation(P>0.05).3.Difference in recurrence and metastasis rate and survival rate between HIPEC group and control groupThere was no significant difference in the recurrence and metastasis rate and survival rate between the HIPEC group and the control group at 6 months,1 year,and 2 years after surgery(P>0.05).Conclusions:1.Early hyperthermic intraperitoneal chemotherapy with lobaplatin does not increase the incidence of postoperative complications in patients with colorectal cancer,and has no significant effect on postoperative recovery of patients.Therefore,hyperthermic intraperitoneal chemotherapy is safe for patients with colorectal cancer.2.Early hyperthermic intraperitoneal chemotherapy with lobaplatin did not significantly improve short-term recurrence and metastasis rates and survival rates in patients with colorectal cancer,but it could reduce the positive rate of tumor markers,and its clinical efficacy needs to be confirmed by more clinical evidences... |
PDF Full Text Request